Draft NICE guidance supports the use of mirabegron for the treatment of symptoms associated with overactive bladder in certain patients

Source: NICE Area: News The National Institute for Health and Clinical Excellence (NICE) has issued draft guidance for consultation on the use of mirabegron for the treatment of symptoms associated with overactive bladder. The guidance makes the following preliminary recommendations:   1. Mirabegron is recommended as an option for treating the symptoms of overactive bladder only for people in whom antimuscarinic drugs are contraindicated or clinically ineffective, or have unacceptable side effects.   2. People currently receiving mirabegron whose condition does not meet the criteria above should be able to continue treatment until they and their clinician consider it appropriate to stop.   The closing date for comments on this draft guidance is 22nd March 2013.
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news